BTIG Rates Spyre Therapeutics (SYRE) buy, $112 Price Target

BTIG maintained its buy rating on Spyre Therapeutics with a $112 price target, a 26.78% upside from the current price.

By TradeTexts Research Desk · Published Jun 16, 2026, 6:00 AM EDT · Updated Jun 22, 2026, 12:02 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

BTIG rated Spyre Therapeutics, Inc. ($SYRE) "buy" with a $112 price target on June 16, 2026.

Since the rating, $SYRE is up 16.4% after 1 week, up 12.8% after 1 month and down 4.2% to date (from the $83.41 close on Jun 16, 2026).

SYRE Spyre Therapeutics, Inc.

$79.90 +161.28% year to date

Daily close · Oct 16, 2026

Key Points

BTIG reiterated its buy rating on Spyre Therapeutics with a $112 price target on June 16, 2026.
BTIG's $112 price target implies 26.78% upside from Spyre Therapeutics, Inc.'s ($SYRE) current $88.34 share price.
Shares of Spyre Therapeutics traded at $83.58, with a market cap of about $7.26 billion.
Insider trading activity included planned sales and purchases by executives in early June 2026.

Get $SYRE trade alerts by text

We text you when insiders, Congress or big funds trade $SYRE. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Spyre Therapeutics, Inc. alert may contain errors. Disclosures

BTIG has reiterated its buy rating on Spyre Therapeutics, Inc. (NasdaqGS: SYRE), with a price target of $112. This update came on June 16, 2026, as the stock traded at $83.58.

Spyre Therapeutics, Inc. Stock Down 2.1%

Shares of Spyre Therapeutics recently traded at $83.58 on the NasdaqGS. The company has a market cap of approximately $7.26 billion. Although Spyre is not currently profitable, its forward P/E ratio is not meaningful. The beta of the stock is 3.063, indicating higher volatility compared to the market. Over the past year, the stock has ranged from $13.93 to $84.69, with a 50-day moving average of $70.59 and a 200-day moving average of $39.84.

12-month forecast

$SYRE price target

Spyre Therapeutics, Inc. daily closes and this analyst's $112 target. Not advice.

Recent Earnings

Spyre Therapeutics is not currently profitable with an EPS of -$2.12. The company's return on equity is negative at -31.1%. The next earnings report is expected on August 4, 2026.

Insider Buying and Selling at Spyre Therapeutics, Inc.

In early June 2026, several insiders engaged in trading activities. Sloan Sheldon, the Chief Medical Officer, sold 8,333 shares at $75.00 per share under a planned sale on June 3, 2026. Additionally, Sheldon purchased 8,333 shares at $27.46 per share on the same day. Scott Burrows, the CFO, bought 7,500 shares at $14.50 on June 1, 2026, and also sold 7,500 shares at $71.06 under a planned sale. CEO Cameron Turtle sold 15,000 shares at $70.43 under a planned sale on June 1, 2026.

Analysts Set New Price Targets

On June 16, 2026, BTIG maintained its buy rating on Spyre Therapeutics with a price target of $112. Earlier, on June 4, 2026, Deutsche Bank also maintained a buy rating with a target of $115. Other analysts, including Citigroup and Stifel, have maintained buy ratings with targets of $97 and $107, respectively. The consensus among analysts is a strong buy, with an average target price of $96.07 across 15 opinions.

About Spyre Therapeutics

Spyre Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts. It focuses on developing therapeutics for inflammatory bowel disease and rheumatic diseases. Their lead product, SPY001, is a monoclonal antibody in phase-2 clinical trials for treating ulcerative colitis and Crohn's disease. The company also has several other treatments in various stages of development. Led by CEO Dr. Cameron Turtle, Spyre employs 112 people.

Bottom Line

BTIG's reaffirmation of a buy rating with a $112 target suggests confidence in Spyre Therapeutics' potential. The company's stock has shown significant volatility, but with ongoing developments in its clinical pipeline, it remains a focus for investors. As always, remember that 13F filings and analyst ratings are backward-looking and may not represent the most current positions or opinions.